Clinical trial
MEN-10755 in Treating Patients With Progressive Prostate Cancer That Has Not…
NCT00027781 · European Organisation for Research and Treatment of Cancer - EORTC, Other · Completed
Key facts
| NCT number | NCT00027781 |
|---|---|
| Title | MEN-10755 in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone Therapy |
| Official title | Open Label Phase II Study of MEN-10755 Administered Every 3 Weeks in Patients With Progressive Hormone Refractory Prostate Cancer |
| Lead sponsor | European Organisation for Research and Treatment of Cancer - EORTC, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | sabarubicin |
| Enrollment | 37 |
| Start date | Aug 1, 2001 |
| Primary completion | Mar 1, 2003 |
| First posted | Jan 27, 2003 |
| Last update posted | Jul 24, 2012 |
| Countries | Belgium, France, Germany, Israel, Spain, Switzerland |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: